, the question was raised as to whether somatostatin could be used as a diagnostic and therapeutic agent in patients with hypersécrétion of insulin. In the following, five such cases will be reported.
The hypothalamic growth hormone release-inhibiting hormone, somatostatin, isolated by Brazeau et al. (1973) , was soon found also to be a potent in¬ hibitor of glucose induced insulin release in man (Alberti et al. 1973 ; Mortimer et al. 1974; Efendic 8c Luft 1975) and animals (Alberti et al. 1973; Efendic et al. 1974 ). In the light of this finding and the recent observation that somatostatin or a somatostatin-like peptide is produced in the pancreatic islets of guinea-pigs and rats , as well as man (Polak et al. 1975) , the question was raised as to whether somatostatin could be used as a diagnostic and therapeutic agent in patients with hypersécrétion of insulin. In the following, five such cases will be reported. Methods.
-
The glucose infusion test (GIT) was performed as described previously (Cerasi Se Luft 1967) with one modification: only 250 mg of glucose per kg body weight were injected rapidly, followed by a 60 min infusion of 10 mg of glucose per kg per min (in the original GIT the doses were 500 and 20 mg). Blood samples for the determination of glucose and insulin were drawn at 10 min intervals during the infusion and at 20 min intervals during the following hour.
In the GIT-somatostatin test, somatostatin was given as a priming intravenous in¬ jection 30 min before GIT, followed by intravenous infusion of somatostatin during 60 min. The priming dose used was 0.003 mg per kg, and the dose applied during the infusion 0.004 mg per kg. Additional blood samples were taken 40, 30 and 10 min before GIT.
Blood glucose was determined enzymatically on whole blood with a commercial glucose oxidase preparation (AB Kabi, Stockholm). Insulin in plasma was measured radioimmunologically by the double antibody technique of Hales Se Rändle (1963) .
In all studies, highly purified cyclic linear somatostatin was used, produced by the Research Department of the Kabi Group, Stockholm. Another obvious disadvantage of somatostatin treatment of hyperinsulin¬ aemia is the simultaneous inhibition of the release of growth hormone and glucagon. In this connection, it is of considerable interest that an analogue of somatostatin has been produced which preferentially inhibits insulin release (Efendic et al., in press).
RESULTS

